Sumitomo Pharma Co., Ltd.
SMDPY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $108 | $106 | $112 |
| % Growth | -99.3% | 2.2% | -6% | – |
| Cost of Goods Sold | $0 | $44 | $40 | $41 |
| Gross Profit | $0 | $64 | $66 | $71 |
| % Margin | 61.7% | 59.2% | 62.5% | 63.1% |
| R&D Expenses | $0 | $8 | $13 | $10 |
| G&A Expenses | $0 | $0 | $4 | $0 |
| SG&A Expenses | $0 | $36 | $50 | $41 |
| Sales & Mktg Exp. | $0 | $0 | $25 | $0 |
| Other Operating Expenses | $0 | -$0 | -$12 | -$2 |
| Operating Expenses | $0 | $43 | $50 | $50 |
| Operating Income | $0 | $20 | $16 | $21 |
| % Margin | 19.5% | 18.9% | 14.7% | 19% |
| Other Income/Exp. Net | $0 | -$8 | -$22 | $35 |
| Pre-Tax Income | $1 | $12 | -$6 | $56 |
| Tax Expense | -$0 | $1 | -$9 | $3 |
| Net Income | $1 | $11 | $2 | $53 |
| % Margin | 73.6% | 10.4% | 2.3% | 47.5% |
| EPS | 1.5 | 28.21 | 6.08 | 134.53 |
| % Growth | -94.7% | 364% | -95.5% | – |
| EPS Diluted | 1.5 | 28.21 | 6.08 | 134.53 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $35 |
| Interest Expense | $0 | $8 | $22 | $0 |
| Depreciation & Amortization | $0 | $5 | $6 | $6 |
| EBITDA | $1 | $26 | $6 | $27 |
| % Margin | 72.3% | 24.3% | 5.3% | 24.4% |